Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 10/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825740 | 0.79 | AHR (0.61) | AHRPIK3CGAPPTSHRMAPK10 | |
| SCHEMBL24656059 | 0.79 | PIK3CG (0.43) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30842048 | 0.76 | AHR (0.51) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL618586 | 0.76 | AHR (0.60) | AHRPIK3CGAPPTSHRMAPK10 | |
| SCHEMBL27038621 | 0.76 | AHR (0.60) | AHRPIK3CGAPPTSHRMAPK10 | |
| SCHEMBL4325240 | 0.76 | PIK3CG (0.42) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL10044580 | 0.76 | PIK3CG (0.44) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL15415685 | 0.76 | AHR (0.51) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| Bromide SCHEMBL1260233 | 0.74 | PIK3CG (0.41) | AHRPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1933137 | 0.73 | PIK3CG (0.52) | AHRPIK3CGPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | claimed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-12606556-B2 | TYK-2 inhibitor | BEONE MEDICINES I GMBH (CH) | 2026-04-21 | — | — | US | disclosed |
| US-12522583-B2 | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| CN-115003667-B | TYK-2 inhibitors | 百济神州有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025072392-A1 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008116139-A2 | N-HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | TYK2, TXK, JAK1 | AHR 232/4885PIK3CG 1556/4885PIK3CD 1885/4885 |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | AHR 1842/4885PIK3CG 1911/4885PIK3CD 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.